The Role of p53 Gene in Cervical Carcinogenesis

Garima, .; Pandey, Sarita; Pandey, Laxman; Saxena, Ashok Kumar; Patel, Nidhi

doi:10.1007/s13224-015-0754-1

Cited by 11 publications

(8 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Alterations in the p53 gene are closely associated with invasive cancers as a result of loss of tumour suppressor function. The overexpression of p53 biomarker have been shown in cervical cancers [ 59 , 60 ]. Table 1 outlines HIV-associated cancer biomarkers.…”

Section: The Genetics Of Molecular Biomarkersmentioning

confidence: 99%

HIV-Associated Cancer Biomarkers: A Requirement for Early Diagnosis

Dlamini

Mbele

Makhafola

et al. 2021

IJMS

View full text Add to dashboard Cite

Globally, HIV/AIDS and cancer are increasingly public health problems and continue to exist as comorbidities. The sub-Saharan African region has the largest number of HIV infections. Malignancies previously associated with HIV/AIDS, also known as the AIDS-defining cancers (ADCs) have been documented to decrease, while the non-AIDS defining cancer (NADCs) are on the rise. On the other hand, cancer is a highly heterogeneous disease and precision oncology as the most effective cancer therapy is gaining attraction. Among HIV-infected individuals, the increased risk for developing cancer is due to the immune system of the patient being suppressed, frequent coinfection with oncogenic viruses and an increase in risky behavior such as poor lifestyle. The core of personalised medicine for cancer depends on the discovery and the development of biomarkers. Biomarkers are specific and highly sensitive markers that reveal information that aid in leading to the diagnosis, prognosis and therapy of the disease. This review focuses mainly on the risk assessment, diagnostic, prognostic and therapeutic role of various cancer biomarkers in HIV-positive patients. A careful selection of sensitive and specific HIV-associated cancer biomarkers is required to identify patients at most risk of tumour development, thus improving the diagnosis and prognosis of the disease.

show abstract

Section: The Genetics Of Molecular Biomarkersmentioning

confidence: 99%

HIV-Associated Cancer Biomarkers: A Requirement for Early Diagnosis

Dlamini

Mbele

Makhafola

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…The interaction between S100-A4 and p53 promotes p53 degradation 50 , an important tumor suppressor. Loss of protein function prevents the cell cycle from progressing moving on to the next phase, which may result in the development of tumors [51][52][53] , such as brain tumors 54 , breast 55 , colon 56 and lung 57 carcinomas. S100-A4 poses as a strong biomarker candidate to indicate early tumor detection and also offers possible evidence of metastatic events of these tissues, being identified in the breast 58 , brain 59 , and liver 60 cancer metastasis.…”

Section: Ccn Family Member 3 (Nov)mentioning

confidence: 99%

Proteomics pinpoints alterations in grade I meningiomas of male versus female patients

Silva

Wippel

Santos

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Meningiomas are among the most common primary tumors of the central nervous system (cnS) and originate from the arachnoid or meningothelial cells of the meninges. Surgery is the first option of treatment, but depending on the location and invasion patterns, complete removal of the tumor is not always feasible. Reports indicate many differences in meningiomas from male versus female patients; for example, incidence is higher in females, whereas males usually develop the malignant and more aggressive type. With this as motivation, we used shotgun proteomics to compare the proteomic profile of grade I meningioma biopsies of male and female patients. Our results listed several differentially abundant proteins between the two groups; some examples are S100-A4 and proteins involved in RNA splicing events. For males, we identified enriched pathways for cell-matrix organization and for females, pathways related to RNA transporting and processing. We believe our findings contribute to the understanding of the molecular differences between grade I meningiomas of female and male patients. Meningioma is a high incidence tumor that typically emerges at the arachnoid cap or meningothelial cells of the meninges 1 , commonly from intracranial, intraspinal, or orbital locations, and are usually benign, slow-growing tumors 2. Resonance imaging and molecular markers are frequently used for preliminary diagnosis; yet, surgical removal of the tumor is necessary for histological diagnostic confirmation and improved life quality 1,2. When surgery for total removal of the tumor is not feasible, adjuvant radiation may be used 1. The World Health Organization (WHO) classifies meningiomas according to their histopathological characteristics, mitotic count, and brain invasion pattern in (i) grade I, also known as benign meningiomas (BMs, about 80% of termed cases); (ii) grade II, or atypical meningiomas (AMs, 17% of termed cases); and (iii) grade III, the malignant meningiomas (MMs, 3% of termed cases) 3. Although this classification is valid in terms of prognosis, it lacks information about tumor aggressiveness and recurrence rates 2. Controversially, most recurrent meningiomas correspond to BMs; their metabolic phenotype indicates an aggressive metabolism, resembling that of AM 4. Female patients present approximately double the incidence of meningiomas compared to men 1. Interestingly, the main risk factor for meningiomas is related to hormonal changes as these tumors present hormones receptors (i.e., progesterone and estrogen) 5,6. Moreover, association between meningiomas and breast cancer, mainly due to similar hormonal signaling and genetic predisposition, has also been reported 5. The fact that women diagnosed with breast cancer are more likely to develop meningioma may also justify the higher incidence of this tumor in females 7,8. In general, women usually develop the benign form while males develop the malignant type of meningioma, the aggressive grade III 6. Besides gender, other risk factors associated with this disease include...

show abstract

“…Повреждение ДНК и другие стрессовые сигналы вызывают увеличение уровня белка р53, что ведет к задержке роста опухоли посредством остановки клеточного цикла и предупреждения репликации поврежденной ДНК. Вирусные онкопротеины нарушают клеточный цикл и обеспечивают ингибирование p53-опосредованного апоптоза [19].…”

Section: механизм действия впч на регуляцию клеточного циклаunclassified

Ongoing challenges and future directions of human papillomavirus vaccination

Аляутдина

Прилуцкая

2020

Bezopasnost' i risk farmakoterapii

View full text Add to dashboard Cite

Федеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И. М. Сеченова» Министерства здравоохранения Российской Федерации, ул. Трубецкая, д. 8, стр. 2, Москва, 119991, Российская Федерация Резюме. Рак шейки матки, вызываемый вирусом папилломы человека (ВПЧ) 16 и 18 типов, является одним из самых распространенных злокачественных новообразований у женщин. Другие высокоонкогенные типы вируса способствуют возникновению рака влагалища, вульвы, пениса, анального канала, злокачественных новообразований головы и шеи. Низкоонкогенные типы ВПЧ, такие как 6 и 11, могут быть причиной аногенитальных бородавок и папилломатоза верхних дыхательных путей. Эти заболевания возможно предотвратить с помощью вакцинации до инфицирования вирусом. Цель работы: систематизация актуальных данных по профилактике ВПЧ-ассоциированных заболеваний с помощью вакцинации. В настоящее время в мире зарегистрированы три вакцины против вируса папилломы человека -Церварикс ® , Гардасил ® и Гардасил ® 9. Обширные клинические и пострегистрационные исследования свидетельствуют о безопасности и высокой эффективности данных вакцин (до 100%) в отношении возникновения интраэпителиальных неоплазий шейки матки, вульвы и влагалища при введении их пациенткам, не инфицированным данными типами вируса ранее. Однако существует ряд нерешенных вопросов, стимулирующих проведение дальнейших клинических исследований по поиску универсальной вакцины. Прежде всего эффективность указанных вакцин ограничена включенными типами ВПЧ. Только в 2011 г. был поднят вопрос о необходимости вакцинации лиц мужского пола. Также периодически происходит пересмотр рекомендаций по кратности вакцинации вследствие появления новых результатов исследований иммуногенности вакцины. Снижение кратности иммунизации особенно актуально для развивающихся стран с ограниченными финансовыми ресурсами и высокой заболеваемостью раком шейки матки. Таким образом, для достижения элиминации ВПЧ во всем мире необходимо проведение глобальных программ вакцинации, в том числе оптимальных по доступности и кратности вакцинации для развивающихся стран, увеличение охвата вакцинацией по возрасту и полу, а также расширение программ скрининга в области онкологии. Ключевые слова: вирус папилломы человека; ВПЧ вакцинация; церварикс; гардасил; рак шейки матки

show abstract

The Role of p53 Gene in Cervical Carcinogenesis

Cited by 11 publications

References 12 publications

HIV-Associated Cancer Biomarkers: A Requirement for Early Diagnosis

HIV-Associated Cancer Biomarkers: A Requirement for Early Diagnosis

Proteomics pinpoints alterations in grade I meningiomas of male versus female patients

Ongoing challenges and future directions of human papillomavirus vaccination

Contact Info

Product

Resources

About